Background macular Shape Background macular Shape Background macular Shape
Grants > Interaction of Diet and Genotype in AMD Pathogenesis Updated On: Jan. 23, 2025
Macular Degeneration Research Grant

Interaction of Diet and Genotype in AMD Pathogenesis

Principal Investigator

Caroline Zeiss, PhD

Yale University

New Haven, CT, USA

About the Research Project

Program

Macular Degeneration Research

Award Type

Standard

Award Amount

$100,000

Active Dates

April 01, 2007 - March 31, 2009

Grant ID

M2007097

Goals

This study aims to develop a robust early-onset mouse model of AMD for therapeutic testing. These experiments also provide insight into how diet interacts with predisposing genetic burden to create AMD pathology. Understanding these relationships will enhance the capacity of clinicians to counsel at-risk patients.

Summary

Age-related macular degeneration is the predominant cause of vision loss in adults over 65. There is no single cause for this disease, and it results from complex interactions of genetic predisposition and environmental influences. Consequently, it is difficult to predict and treat. The lack of effective treatment stems from both the complexity of the disease and the lack of good animal models to study it. We have been able to obtain a mouse model that carries a mutation in an important macular degeneration gene – Factor H. Using this mouse as the basis of our experiments, we will superimpose additional mutations (ApoE and CCr2) and environmental conditions (high-fat diet). We expect that these interventions hasten the onset of AMD in mice. We will also determine whether mice carrying a mutation in Tlr4, a gene that has recently been associated with AMD, develop AMD-like lesions after normal or high-fat feeding. This intends to develop a robust early-onset mouse model of AMD for therapeutic testing. These experiments also provide insight into how diet interacts with predisposing genetic burden to create AMD pathology. Understanding these relationships will enhance the capacity of the clinician to council at-risk patients.